[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100254087":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":36,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Sequenom, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-hematological Cancer Cohort",null,"Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.",[13],{"name":14,"affiliation":5,"role":15},"Sue Beruti, MD","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Graham McLennan","CONTACT","(858) 202-9162","gmclennan@sequenom.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Idaho Urology","RECRUITING","Boise","Idaho","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-116.20345,43.6135,{"lat":34,"lon":33},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100254087","specimen-collection-from-patients-with-non-hematologic-cancer-for-use-in-development-of-a-liquid-biopsy-assay-100254087",false,"NCT02586389","Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay","Collection of Whole Blood and Tissue Specimens from Patients Diagnosed with Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA","Inclusion Criteria:\n\n* Subject is 18 years of age or older;\n* Subject is willing to provide written informed consent;\n* Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;\n\n  1. residual tumor tissue available for testing by the Sponsor; or\n  2. genomic profiling results from an IVD or LDT assay performed on tumor biopsy tissue; or\n  3. an invasive procedure (biopsy, surgery) scheduled following the Baseline Visit from which residual tumor tissue can be available for testing by the Sponsor.\n* Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.\n\nExclusion Criteria:\n\n* Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.\n* Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.\n* Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).\n* Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.","ALL","18 Years",{"count":48,"type":49},3000,"ESTIMATED","OBSERVATIONAL","This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).",[53],"Non-hematologic Cancer","2024-10-11",{"date":56,"type":57},"2024-10-16","ACTUAL",{"date":59,"type":57},"2015-10-13",{"date":61,"type":49},"2027-10-31",{"name":5,"class":6},1]